Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023 - Morphic Holding (NASDAQ:MORF)

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen across key measures at

Related Keywords

Denmark ,Poland ,United States ,Copenhagen ,Køavn ,Dan Cui ,Laurent Peyrin Biroulet ,Adrian Ray ,Chris Erdman ,Silvio Danese ,Ali Hussain ,Yujun Wu ,Sarah Hammer ,Michael Choi ,Maloy Mangada ,Bruce Rogers ,Pbruce Sands ,Burrillb Crohn ,Fangui Sun ,Oladele Babalola ,Brian Feagan ,Jaroslaw Kierkus ,Peter Linde ,Sharon Brown ,Brihad Abhyankar ,Stefan Schreiber ,Carolyn Soo ,Kerry Mcconie ,Dooyoung Lee ,Cuyue Tang ,Exchange Commission ,Icahn School Of Medicine At Mount Sinai ,Securities Exchange ,United European Gastroenterology Week ,Robarts Histopathology Index ,Mayo Clinic Score ,Icahn School ,Mount Sinai ,Henry Janowitz Division ,Mount Sinai Health ,Modified Mayo Clinic Score ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,